Mutations in SRPX2 (Sushi-Repeat Protein, X-linked 2) cause rolandic epilepsy with speech impairment (RESDX syndrome) or with altered development of the speech cortex (bilateral perisylvian polymicrogyria). The physiological roles of SRPX2 remain unknown to date. One way to infer the function of SRPX2 relies on the identification of the as yet unknown SRPX2 protein partners. Using a combination of interactome approaches including yeast two-hybrid screening, co-immunoprecipitation experiments, cell surface binding and surface plasmon resonance (SPR), we show that SRPX2 is a ligand for uPAR, the urokinase-type plasminogen activator (uPA) receptor. Previous studies have shown that uPAR 2/ 2 knock-out mice exhibited enhanced susceptibility to epileptic seizures and had brain cortical anomalies consistent with altered neuronal migration and maturation, all features that are reminiscent to the phenotypes caused by SRPX2 mutations. SPR analysis indicated that the p.Y72S mutation associated with rolandic epilepsy and perisylvian polymicrogyria, led to a 5.8-fold gain-of-affinity of SRPX2 with uPAR. uPAR is a crucial component of the extracellular plasminogen proteolysis system; two more SRPX2 partners identified here, the cysteine protease cathepsin B (CTSB) and the metalloproteinase ADAMTS4, are also components of the extracellular proteolysis machinery and CTSB is a well-known activator of uPA. The identification of functionally related SRPX2 partners provides the first and exciting insights into the possible role of SRPX2 in the brain, and suggests that a network of SRPX2-interacting proteins classically involved in the proteolytic remodeling of the extracellular matrix and including uPAR participates in the functioning, in the development and in disorders of the speech cortex.
INTRODUCTION
How the language areas develop and function represents a crucial scientific issue: language is specific to the human species and remains a mysterious process from several viewpoints. Language has been widely studied through various approaches and in different fields including linguistics, anthropology, archeology, psychology, philosophy, medicine and biology. While considerable progress has been made in the recent years in the analysis of the brain language areas and networks by functional neuroimaging, very little is known on the molecular mechanisms that lead to the appropriate and precise development and functioning of the complex and higher-order anatomical architecture that must be associated with language processing. Convergent evidence at the clinical, electrophysiological and neuroimaging levels has indicated that the perisylvian areas (from Broca's area anteriorly to Wernicke's area posteriorly) play a critical role in the processes associated with expressive and receptive language. Although comparative analyses have led to the identification of a few candidate genes showing differential expression in the perisylvian area during developmental patterning of the cerebral cortex (1, 2) , this type of approach may not distinguish between the genes that act as key-players and the genes that would only show differential expression as a consequence of other molecular processes. From this viewpoint, the study of human pathologies in which language areas and networks do not develop or function properly represents a promising and quite unique way to start unraveling the mechanisms that are related to language processing. Indeed, the study of one single and large family with autosomal dominant inheritance of oral and speech dyspraxia (MIM 602081) led to the identification of the first 'speech' gene, namely FOXP2, that encodes a transcription factor of the forkhead domain family (3) . Since then, studies on in vitro and in vivo models have been done that aim to decipher the cellular and molecular mechanisms that may sustain speech processing and evolution through FOXP2-mediated regulation of transcription (4 -6) .
SRPX2 (Sushi-Repeat Protein, X-linked 2) is another gene that can be directly associated with altered speech production and abnormalities in brain speech areas. Indeed, mutations in SRPX2 cause epileptic, speech and developmental disorders of the language cortex (MIM 300642) (7) . The pathogenic p.N327S mutation leads to gain-of-glycosylation of the mutant SRPX2 protein and causes seizures of the rolandic (sylvian) brain area with oral and speech dyspraxia and with mental retardation (MIM 300643). The other disease-causing mutation (p.Y72S) occurs in a functional domain of SRPX2 and was identified in one affected male with rolandic seizures and bilateral perisylvian polymicrogyria and in his female relatives with no or mild mental retardation only (MIM 300388). As SRPX2 mutations cause defects of the rolandic and perisylvian regions, this gene actually represents a promising key to start understanding the functioning and the development of the speech areas in both physiological and pathological conditions. SRPX2 (Genbank NP_055282) is a secreted protein of 465 aminoacids that contains three consensus sushi repeat motifs of approximately 60 aminoacids each. Sushi domains exist in a large variety of organisms from viruses to mammals. They are frequently found in proteins of the complement system-sushi domains are also known as CCP (complement control protein) modules-and in various others including members of the selectin family (8) . In the brain, sushi domains may be the basis for the distinct subcellular localizations and physiological actions on synaptic plasticity of the two GABA B1 subunit isoforms (9, 10) . The seizure-related murine protein Sez-6 contains sushi domains and participates in the excitability of cortical neurons (11) . In Drosophila melanogaster, the sushi-containing protein hikaru genki is secreted at synaptic clefts and is involved in the development of the central nervous system (12) . Together with our own findings on the role of SRPX2 in human brain pathology (7) , all these data indicate that proteins with sushi domains participate in important functions in the brain, probably by mediating protein interactions with a large variety of cell adhesion molecules. SRPX2 (previously known as SRPUL) had been first described in leukemia cells as a secreted protein with dysregulated expression at the transcriptional level (13) . Despite its putative importance in brain functioning and development and its involvement in pathologies of the language cortex, the actual role of SRPX2 remains unknown to date. Sushi domains have been involved in various protein -protein interactions, as shown for instance in the interaction of neurocan with L1 (14) , in the C4b-binding protein/streptococcal M protein interaction (15) , or in the binding of IL15 on its alpha receptor (16, 17) . Generally, one powerful way to infer the function of a given protein may rely on the identification of its molecular partners. As an example, the function of the epitempin protein LGI1 that is mutated in temporal lobe epilepsies has long remained unpredictable until its subcellular expression was analyzed (18) and the two first LGI1 partners were proposed (19, 20) . Such an interactome strategy looks particularly attractive in the case of proteins such as SRPX2 that contain modules highly suspected to drive protein interactions. In the present study, we have investigated potential binding partners for the sushi-containing protein SRPX2. We show that SRPX2 is a novel ligand for the urokinase-type plasminogen activator receptor (uPAR) as well as for other members of the extracellular proteolysis system, and that a disease-associated mutant SRPX2 protein displays increased affinity for uPAR. Altogether, our data bring novel and exciting insights on the physiological and pathological processes associated with the functioning and the development of the brain speech areas.
RESULTS

Selection of putative SRPX2 partners by yeast two-hybrid screening
The yeast two-hybrid screening was performed with human SRPX2 full-length coding sequence as a bait and a human adult brain partial cDNA library as target. This yielded about 40 polypeptides, among which 19 corresponded to proteins with known or predicted subcellular localizations consistent with an actual interaction with the secreted SRPX2 protein, i.e. those proteins are known or are predicted to be extracellular and/or to belong to the plasma membrane and the intracellular membrane compartments. In the case of plasma membrane proteins, the domains of interaction as detected by the yeast two-hybrid screening actually corresponded to the extracellular parts of the corresponding fulllength proteins (Table 1) .
Validation of putative SRPX2 partners by co-IP experiments
In order to confirm the interactions of SRPX2 with some of its putative partners as identified by two-hybrid screening, co-immunoprecipitation (co-IP) experiments were performed. Six out of the 19 putative SRPX2 partners [ADAMTS4, (Table 2) , and (ii) because constructs corresponding to the six full-length selected proteins could be obtained and validated at the time this analysis was set up. The sequences of all six corresponding full-length open reading frames subcloned into pReceiver-M03 or into pAcGFP-N1 expression vectors were verified in each construct and any DNA mutation reverted by in vitro mutagenesis wherever appropriate (Supplementary Material, Table S1 ) in order to obtain the canonical wild-type proteins of interest. All six fusion proteins that could be produced after transient transfection in the appropriate cell line had a GFP tag at the C-terminus, thus allowing fluorescent and immunological detections. Either of the six constructs was co-transfected with a construct allowing the expression of the SRPX2 protein fused with a myc epitope (pcDNA4-SRPX2). Among the six putative SRPX2 partners, one (NELL2) did not yield detectable co-expression with SRPX2, either in HEK293T cells or in COS-7 cells (data not shown). For the five remaining proteins, co-IP experiments were then performed using myc as precipitating antibody. Neither PCDH10 nor WIF1 yielded detectable western blot signals after precipitation with myc antibody, indicating that those two proteins did not associate with SRPX2, at least in the experimental conditions used here (Supplementary Material, Fig. S1A ). In contrast, uPAR, CTSB and ADAMTS4 fusion proteins were efficiently and reproducibly co-immunoprecipitated in the presence of the SRPX2 construct, as western blot analysis revealed that the anti-GFP antibody reacted with bands at the expected sizes (uPAR-GFP: 83 kDa; CTSB-GFP: 64 kDa; ADAMTS4-GFP: 117 kDa) of each corresponding fusion protein (Fig. 1) . As a control, no immunoprecipitation of either protein was obtained in the absence of the SRPX2-myc fusion protein (Fig. 1) , and a GFP protein directed toward the secretory pathway through its fusion with a signal peptide at its N-terminus, did not co-immunoprecipitate with SRPX2 ( Supplementary Material, Fig. S1B ). Together with the yeast two-hybrid experiments, the co-IP data obtained here confirmed that uPAR, CTSB and ADAMTS4 interacted with SRPX2.
Expression analysis of SRPX2 and uPAR in the human and rat brains and SRPX2/uPAR co-IP in vivo Among the three SRPX2 partners as confirmed just above (uPAR, CTSB and ADAMTS4), uPAR represented our first and prioritary interest. uPAR is a key component of the plasminogen activation system (21) and plays an important role in various processes such as coagulation, immunity, angiogenesis, cell proliferation, adhesion and migration. Interestingly and despite its pleiotropic function, the knock-out of uPAR in mice mainly leads to enhanced susceptibility to epileptic seizures and to altered neuronal migration and maturation in the neocortex (22, 23) , all features that are highly consistent with the phenotypes caused by SRPX2 mutations in human (7) .
Reverse transcription polymerase chain reaction (RT -PCR) experiments were performed to study the spatio-temporal pattern of expression of SRPX2 and uPAR transcripts in human and rat brain tissues. SRPX2 and uPAR transcripts could be detected in all brain samples and at all developmental stages that were analyzed ( Fig. 2A) . We then performed immunohistochemistry experiments to ask whether the human SRPX2 and uPAR proteins were expressed in the same brain territories, and in the rolandic area particularly. The list was elaborated after selection based upon the known and/or predicted subcellular localizations of the corresponding proteins. Access numbers are given according to Genbank at NCBI (http://www.ncbi.nlm.nih.gov/). A confidence score (PBSc, for Predicted Biological Score) was attributed to each interaction as previously described (59) . For a given protein, NDC corresponds to the number of different clones that were identified by the yeast two-hybrid screening. When more than one type of clone was identified (PBSc A-C), the clone sequence (seq.) that is indicated corresponds to the sequence shared in common by the different clones. DOI, domain of interaction; nt, nucleotides; AA, amino acids.
Samples corresponding to the rolandic and to the lateral temporal areas and taken from two non-epileptic autopsy control individuals were analyzed. In all human samples, uPAR and SRPX2-positive neurons were detected in the same areas ( Fig. 2B ; Supplementary Material, Fig. S2 ). Those data demonstrated expression of both SRPX2 and uPAR in the rolandic area. We next examined the temporo-spatial expression patterns of the orthologous Srpx2 and Upar rat proteins in the embryonic brain (E16.5) as well as in the brain at birth (P0) and in adults. These experiments showed co-expression of Srpx2 and Upar proteins at all three stages ( Fig. 2C ; Supplementary Material, Fig. S2 ). In particular, these data indicated that the Srpx2 and Upar rat proteins are expressed at the same time at a developmental stage (E16.5) that is crucial for neuronal migration. We next tested whether the human SRPX2 and uPAR proteins associated in the rolandic area. Protein extracts from this brain region were subjected to immunoprecipitation with anti-SRPX2 antibody. Western blot with anti-uPAR antibody revealed a specific band corresponding to the expected size (55 kDa) of the N-glycosylated uPAR protein (Fig. 2D) , confirming that SRPX2 and uPAR directly interact in the human brain area that is the site of physiological and pathological speech processes.
SRPX2 binding to cell-surface uPAR
Next question consisted in testing the binding of SRPX2 to the cell surface of human cells and in asking whether this binding was, at least partly, dependent on uPAR expression. For this purpose, we used COS-7 cells which normally show low expression of uPAR (24) and have been widely used to study uPAR function. As expected, a weak signal was obtained at the surface of non-transfected (parental) COS-7 cells using anti-uPAR antibody (Fig. 3A) . As uPAR is anchored to the plasma membrane via a glycosyl-phosphatidyl-inositol (GPI) group, the pAcGFP1-N1/uPARstop construct was designed in order to remove the GFP tag at the C-terminus, thus allowing overexpression of GPI-anchored exogeneous uPAR at the cell surface. Indeed, much stronger anti-uPAR signals were obtained after pAcGFP1-N1/uPARstop was transiently transfected in COS-7 cells (COS-7/uPAR cells), thus demonstrating efficient expression of exogeneous uPAR at the cell surface (Fig. 3A) . Next, we sought to determine if SRPX2 could bind stronger to COS-7/uPAR cells than to parental COS-7 cells. For this purpose, COS-7 cells cultured independently were transiently transfected with the pAPtag-SRPX2 expression vector containing the full-length SRPX2 coding sequence fused with the alkaline phosphatase (AP) coding sequence, in order to produce secreted recombinant protein SRPX2 in the extracellular medium. In parallel, COS-7 cells were transfected with the non-recombinant AP pAPtag expression vector as a control. In both cases, protein extracts from the extracellular media were recovered and tested for the presence (pAPtag-SRPX2-transfected cells) or the absence (pAPtag-transfected cells) of SRPX2, respectively (Fig. 3B) . These extracts were then used to test for surface binding of COS-7 (parental) and COS-7/uPAR cultured cells. As expected, no AP activity was detected at the cell surface of the parental COS-7 cells and of the COS-7/uPAR cells when the SRPX2-free medium was applied (Fig. 3C) . Weak AP signals were obtained at the surface of parental COS-7 cells when the SRPX2-containing medium was used (Fig. 3C ). This was not unexpected given that, as mentioned and shown earlier (Fig. 3A) , COS-7 cells display low expression of uPAR (24); in addition, the existence at the surface of parental COS-7 cells of one or several SRPX2 receptors different from uPAR cannot be excluded, as other membrane receptors were detected as putative SRPX2 partners, according to our yeast two-hybrid screening data (Table 1) . Consistent with the overexpression of uPAR in COS-7/uPAR cells, pattern of much stronger AP signals was obtained at the surface of COS-7/uPAR cells when the SRPX2-containing medium was applied (Fig. 3C ). Because yeast two-hybrid experiments suggested that SRPX2 and the extracellular part of uPAR directly interact, and because in vivo and in vitro co-IP experiments both confirmed the SRPX2/uPAR association, the binding of SRPX2 to the extracellular portion of uPAR is very likely to sustain the reproducible pattern of SRPX2-dependent AP signals at the surface of uPAR-transfected cells, as compared with uPAR-untransfected cells. Interaction of SRPX2 with the D1 and D2-D3 extracellular domains of uPAR uPAR is a GPI-anchored receptor that contains three extracellular homologous domains of approximately 90 amino acids each (D1, D2 and D3, from N-to C-terminus). The three domains are members of the Ly-6/uPAR/a-neurotoxin protein domain family and may sustain binding of different known uPAR ligands, with classical uPA binding to D1 and complement S-protein (vitronectin; VTN) binding to D2-D3 (21) . In order to precise the site(s) of interaction of SRPX2 with its receptor, uPAR partial coding sequences corresponding to various truncated forms of uPAR ( Fig. 4A) were inserted into the pAcGFP-N1 expression vector and each corresponding construct was co-transfected with pcDNA4-SRPX2 in HEK293T cells. Various truncated proteins that contained either the D1 (uPARD1-GFP) or the D2-D3 (uPARDD1-GFP) domains of uPAR were efficiently and reproducibly co-immunoprecipitated in the presence of the SRPX2 construct, as bands at the expected sizes of each corresponding truncated protein (uPARD1-GFP: 60 kDa; uPARDD1-GFP: 71 kDa) were revealed by western blot analysis using the anti-GFP antibody (Fig. 4B ). As expected, fusion proteins containing the two first domains (uPARD12-GFP: 71 kDa) or the three D1, D2 and D3 domains (full-length uPAR-GFP: 83 kDa, and uPAR-D123-GFP: 80 kDa, this latter lacking the C-terminus part of uPAR), also co-immunoprecipitated with SRPX2 (Fig. 4B ). Additional bands of lower molecular weights (53 and 62 kDa) could be detected for some of the truncated proteins (uPARD12-GFP and uPARD123-GFP, respectively) and corresponded to non-N-glycosylated forms, as indicated by the decrease in the size of the bands of higher molecular weights when N-glycosidase treatment was applied (data not shown). Overall, the data shown here indicated that SRPX2 can associate both with the D1 and with the D2-D3 extracellular parts of uPAR.
Qualitative and quantitative analysis of the wild-type and mutant SRPX2/uPAR interactions
The two disease-causing mutations found in SRPX2, p.Y72S and p.N327S (7), as well as the unique and human-specific p.R75K evolutive mutation that has appeared in SRPX2 since the human -chimpanzee split 6 -8 millions years ago (25) , may have an effect on the SRPX2/uPAR interaction. Co-IP experiments in co-transfected cells showed that the two disease-causing mutant SRPX2 proteins (p.Y72S and p.N327S) as well as the ancestral chimpanzee SRPX2 protein (Genbank ABN46998) with arginine (R) in place of lysine (K) at position 75 (R 75 ), kept interacting with uPAR ( Fig. 5 ) as well as with the two other SRPX2 partners (CTSB and ADAMTS4) validated here (Supplementary Material, Fig. S3 ). Co-IP experiments excluded a complete loss of interaction between the mutant SRPX2 proteins and uPAR. Alternatively, (some of) the SRPX2 mutations might well have led to quantitative rather than qualitative changes in the SRPX2/uPAR interaction. Surface plasmon resonance (SPR) experiments were thus performed in order to quantify the binding of uPAR with the wild-type and with the mutant and chimpanzee SRPX2 proteins. Wild-type SRPX2, mutant SRPX2 bearing the pathogenic p.Y72S mutation and ancestral chimpanzee protein with R 75 were produced in the yeast Pichia pastoris and protein production was verified by western blot and by mass spectrometry (Supplementary Material, Fig. S4 ). The p.N327S gain-of-glycosylation mutant SRPX2 protein could not be produced in sufficient amount despite several attempts. Recombinant uPAR-GST protein was immobilized on the sensor chip surface and different concentrations of analytes (wild-type, mutant and chimpanzee SRPX2 proteins) were injected over the uPAR sensor chip. As expected, wild-type SRPX2 bound to uPAR, with an apparent affinity (K D ) of 114 nM (Table 3) as determined using the single-cycle Figure 1 . uPAR, CTSB and ADAMTS4 GFP-fusion proteins co-immunoprecipitate with SRPX2-myc in HEK293T cells. Co-IP experiments were performed using anti-myc as precipitating antibody and complexes were resolved by SDS-PAGE, followed by immunoblotting for GFP or myc fusion proteins. (A) pcDNA-SRPX2 and pAcGFP1-uPAR constructs were co-transfected in HEK293T cells and the corresponding proteins efficiently produced (lysate). Proteins precipitated with anti-myc antibody (myc IP) were analyzed by immunoblotting. The anti-GFP antibody detected GFP-tagged uPAR protein at the expected size of 83 kDa. The anti-myc antibody detected myc-tagged SRPX2 protein at the expected size of 58 kDa. No band was obtained when the control vector pcDNA4-sp producing the myc tag with only the signal peptide (sp) of SRPX2 at its N-terminus was co-transfected with pAcGFP-uPAR. (B) pcDNA-SRPX2 and pReceiver-CTSB constructs were co-transfected in HEK293T cells and the corresponding proteins efficiently produced (lysate). Proteins precipitated with anti-myc antibody (myc IP) were analyzed by immunoblotting. The anti-GFP antibody detected GFP-tagged CTSB protein at the expected size of 64 kDa. The anti-myc antibody detected myc-tagged SRPX2 protein at the expected size of 58 kDa. No band was obtained when pcDNA4-sp was co-transfected with pReceiver-CTSB (C). pcDNA-SRPX2 and pReceiver-ADAMTS4 constructs were co-transfected in HEK293T cells and the corresponding proteins efficiently produced (lysate). Proteins precipitated with anti-myc antibody (myc IP) were analyzed by immunoblotting. The anti-GFP antibody detected GFP-tagged ADAMTS4 protein at the expected size of 117 kDa. The anti-myc antibody detected myc-tagged SRPX2 protein at the expected size of 58 kDa. No band was obtained when pcDNA4-sp was co-transfected with pReceiver-ADAMTS4.
Human Molecular Genetics, 2008, Vol. 17, No. 23 3621 kinetic method that consists in sequential injection of increasing concentrations (26, 27) . Consistent with the co-IP data, the p.Y72S mutant SRPX2 protein and the chimpanzee SRPX2 protein also bound to uPAR ( (25) both led to a modification in the in vitro affinity for uPAR: the p.R75K evolutive mutation (from R 75 in non-human primates to K 75 in human) was associated with a decrease in the SRPX2/uPAR affinity, and the p.Y72S pathogenic mutation was associated with an increase in the SRPX2/uPAR affinity.
DISCUSSION
SRPX2 mutations cause disorders of the language cortex and cognition such as rolandic epilepsy with speech dyspraxia (RESDX syndrome) and rolandic epilepsy with bilateral perisylvian polymicrogyria (7) . We show here that the secreted SRPX2 protein is a novel ligand for uPAR, the receptor for the plasminogen activator of the urokinase-type. The SRPX2/uPAR interaction was suggested by yeast twohybrid analysis and was subsequently confirmed both by in vitro and in vivo co-IP experiments and by SPR. As measured by three independent SPR experiments, the average strength of the in vitro SRPX2/uPAR association was at K D ¼ 114 nM. Hence, several independent methods all concluded in favor of the interaction of SRPX2 with uPAR. uPAR is composed of three homologous domains (D1, D2 and D3) that are members of the Ly-6/uPAR/a-neurotoxin protein domain family. While yeast two-hybrid screening had indicated interaction of SRPX2 with the D2-D3 part of uPAR, co-IP experiments with various truncated forms of uPAR showed that SRPX2 could interact not only with D2-D3 but also with the D1 domain of uPAR. Such a versatile binding to either the D1 or the D2-D3 domains had already been demonstrated in the case of kininogen, a well-known uPAR ligand (28) . While other uPAR ligands can classically bind either to D1 in the case of uPA (urokinase plasminogen activator), or to D2-D3 in the case of complement S-protein (VTN) (21), recent structural analyses indicated that all three domains actually participate in the formation of the uPA/uPAR and uPA/ VTN/uPAR complexes (29, 30) . The ligand/receptor SRPX2/uPAR relationship was also further demonstrated by cell surface binding, using a secreted AP fusion protein of SRPX2 that bound much stronger to the surface of COS-7 cells when transfected with uPAR. A secreted uPAR isoform (suPAR) can also be generated and our data do not exclude the possible binding of SRPX2 to both types (secreted and membrane-anchored) of uPAR proteins, as shown in the case of the uPA/uPAR interaction (31).
The weaker but visible binding of SRPX2 to the cell surface of COS-7 cells in the absence of exogeneous uPAR expression might well be due to the basic expression of native uPAR at the surface of COS-7 cells (24) . Alternatively, the existence of other SRPX2 receptors at the cell surface of COS-7 cells is likely, as yeast two-hybrid screening led us to identify several other putative SRPX2 plasma membrane receptors. Generally, the existence of several SRPX2 partners in the central nervous system would be consistent with a pleiotropic role of SRPX2 in the brain, especially if the partners are not all expressed in the same territories, and at the same time during brain development and maturation. As a matter of fact, the two disease-causing SRPX2 mutations reported to date, led to overlapping and related albeit different brain disorders of the speech areas (7) . From this point of view, several putative SRPX2 partners detected by the yeast two-hybrid screening (Table 1) have interesting functions, such as the d2 protocadherin PCDH10. Neither PCDH10 nor WIF1 co-immunoprecipitated with SRPX2 in the experimental conditions used here; they might obviously represent falsepositive interactions with SRPX2. Noteworthingly, mutations in another d2 protocadherin, PCDH19, also lead to epilepsy with cognitive impairment (32) , and the d2 protocadherin PCDH17 shows enriched expression in cortical circuits involved in higher functions, including language (2). Although the co-IP experiments performed here did not confirm a direct SRPX2/PCDH10 association in vitro, an interaction in vivo cannot be ruled out. Moreover, interaction of SRPX2 with the phylogenetically related PCDH17 and PCDH19 proteins (33) is not excluded, as some SRPX2 receptors could have escaped detection by the yeast two-hybrid method.
Demonstration of the SRPX2/uPAR ligand/receptor interaction has important consequences for the understanding of SRPX2 and uPAR functions in the human brain. The uPAR system has got well-known function in a broad range of physiological and pathological processes such as fibrinolysis, immune responses, inflammation, angiogenesis, cell growth and cancer metastasis (21, 34, 35) . In addition to this pleiotropic role, mice carrying a targeted mutation of the Upar gene have brain cortical alterations consistent with the impairment of GABAergic interneurons migration and maturation (22) . GABAergic activity is involved in the susceptibility to epileptic seizures (36) and also participates in the coordinated generation and migration of interneuron and pyramidal populations (37, 38) . Together with the Upar knock-out phenotype, the data presented here strongly suggest that uPAR plays an important role in the human brain as well.
The SRPX2 p.Y72S disease-causing mutation led to 5.8-fold increase in the SRPX2/uPAR affinity in vitro. The quantitative modification of the SRPX2/uPAR interaction may well have participated in the epileptic and polymicrogyric phenotypes caused by p.Y72S. Consistently, and as stated earlier, the murine Upar knock-out model also presented with increased susceptibility to epileptic seizures and with altered neuronal migration and maturation (22) . Moreover, both the SRPX2 and uPAR human proteins showed co-expression in the rolandic area, which is the site of the seizures in the patients. Consistent with the phenotype of abnormal cortical gyration, co-expression of Srpx2 and Upar was also detected at the period of neuronal migration and Figure 5 . Interaction of mutant SRPX2 proteins with uPAR. Either pcDNA-SRPX2 construct (wt, N327S, Y72S or R 75 ) and the pAcGFP1-uPAR construct were co-transfected in HEK293T cells and the corresponding proteins efficiently produced (lysate). Complexes precipitated with anti-myc antibody (myc IP) were resolved by SDS-PAGE, followed by immunoblotting for GFP or myc fusion proteins. The anti-myc antibody detected myc-tagged SRPX2 protein at the expected size of 58 kDa. For all co-IP with wild-type, disease-causing mutant (p.Y72S, p.N327S) and chimpanzee (R 75 ) SRPX2 proteins, the anti-GFP antibody detected GFP-tagged uPAR protein at the expected size of 83 kDa. No band was obtained when the control vector pcDNA4-sp producing the myc tag with only the signal peptide (sp) of SRPX2 at its N-terminus was co-transfected with pAcGFP-uPAR. Pronounced species specificity of the binding of various natural and artificial ligands to uPAR had already been reported (42) . Changes in the SRPX2/uPAR association might have participated in the patterning of the speech areas during higher primates evolution, as the unique and humanspecific evolutive mutation (p.R75K) that distinguishes the human and chimpanzee SRPX2 orthologs (25) and thatlike p.Y72S-has occurred in the critical loop of the first sushi domain of SRPX2 also led to decreased (7.2-fold) SRPX2/uPAR affinity. Remarkably, the human pathogenic (p.Y72S) and the chimpanzee (R 75 ) SRPX2 proteins had uPAR apparent affinities in the same range (K D ¼ 19.6 and K D ¼ 15.8 nM, respectively), whereas the apparent affinity of human wild-type SRPX2 with uPAR was one order of magnitude weaker (K D ¼ 114 nM).
Several known uPAR-mediated pathways might be altered by the p.Y72S SRPX2 pathogenic mutation. Altered proteolysis-independent signaling via various uPAR plasma membrane co-receptors (35) could be involved. Alternatively, alteration of the SRPX2/uPAR interaction might also directly disturb synaptic functioning through the classical proteolytic role of uPAR in the pericellular conversion of plasminogen into plasmin (43) . Interestingly, the plasminogen activators of the urokinase (uPA, the uPAR ligand) and of the tissue (tPA) types have already been associated with cognitive and epileptic phenotypes (44 -46) . Neuronal migration could also be impaired via altered uPAR-dependent cleavage and activation of the precursor of hepatocyte growth factor (HGF) (47) . The participation of SRPX2 in the extracellular matrix proteolysis pathway is a particularly attractive possibility as two more SRPX2 partners identified by yeast two-hybrid and co-IP experiments in the present study, CTSB and the metalloproteinase ADAMTS4, can also act as extracellular proteases. Generally, the remodeling of the extracellular matrix plays critical role in the development and in the functioning of the brain and matrix members of the extracellular proteolysis cascades have already been involved in various brain disorders. Examples include the serine protease neurotrypsin in non-syndromic mental retardation (48) , the cysteine protease inhibitor cystatin B in the progressive myoclonic epilepsy (EPM1) of the Unverricht-Lundborg type (49) and CTSB itself in Alzheimer's disease (50) . CTSB cleaves the inactive form of uPA, and uPAR in turn is cleaved by uPA and by metalloproteases (34) . ADAMTS4 (a disintegrin and metalloproteinase) itself influences neuronal phenotype (51) . CTSB and ADAMTS4 can even be part of the same proteolysis pathway as they both can cleave aggrecan, a sushicontaining member of the matrix proteoglycans that in turn have important functions in regeneration and plasticity of the central nervous system (52) . Together with uPAR, CTSB and ADAMT4 may thus form a single functional network. CTSB and ADAMTS4 still associated with the mutant and chimpanzee SRPX2 proteins that could be studied here; whether such binding is altered quantitatively by SRPX2 mutations remains to be determined.
While numerous studies point for an important role of the ion channel subunits in the genesis of acquired and inherited human epilepsies (53, 54) , alterations in the extracellular proteolysis system might represent an important and underestimated human epileptogenic mechanism as well. Similarly, the SRPX2/uPAR-associated pathways might be involved in bilateral perisylvian polymicrogyria, the molecular mechanisms of which are poorly known (55, 56) . The SRPX2/uPAR interaction identified here thus provides a first key to unravel the function of SRPX2 and of uPAR in the human brain and the complicated and still largely unknown processes that sustain the functioning, the development and disorders of the speech areas such as rolandic epilepsy, speech impairment and perisylvian polymicrogyria-a disorder of brain neuronal migration and maturation leading to abnormal cortical gyration.
Finally, the flexibility of uPAR enables its interaction with a wide variety of ligands (29) . While uPAR interactions with several ligands and co-receptors have already been described (34), as also indicated at the Human Protein Reference Database (http://www.hprd.org/), there still is an intensive search for novel uPAR interacting molecules. It is thus of broad interest to note that SRPX2 as a novel uPAR ligand may represent a novel target for the design of new therapeutic molecules that would regulate some of the numerous and crucial uPARdependent physiological and pathological processes, such as matrix degradation, cell adhesion and migration, clot lysis, proliferation and angiogenesis, apoptosis, cell growth and metastasis.
MATERIALS AND METHODS
Yeast two-hybrid screening
Yeast two-hybrid screening was performed by Hybrigenics, S.A., Paris, France (http://www.hybrigenics.com). The coding sequence for amino acids 24-464 of SRPX2 (GenBank accession number NP_055282) was PCR-amplified and cloned into pB27 as a C-terminal fusion to LexA (N-LexA-SRPX2-C). The construct was checked by sequencing the entire insert and used as a bait to screen a randomprimed human adult brain cDNA library constructed into pP6. pB27 and pP6 derive from the original pBTM116 (57) and pGADGH (58) plasmids, respectively. Ninety-one million clones (9.1-fold the complexity of the library) were screened using a mating approach with Y187 (mat-a) and L40DGal4 (mat-a) yeast strains as previously described 59) . A total of 197 His þ colonies were selected on a medium lacking tryptophan, leucine and histidine. The prey fragments of the positive clones were amplified by PCR and sequenced at their 5 0 end and 3 0 end junctions. The resulting sequences were used to identify the corresponding interacting proteins in the GenBank database (NCBI) using a fully automated procedure. A confidence score (PBSc, for predicted biological score) was attributed to each interaction as previously described (60) .
Reverse transcriptase PCRs
Total RNAs from human autopsy brain samples corresponding to the temporal lobe and to the rolandic area and obtained through the Netherlands Brain Bank from two donors were prepared by Trizol extraction, according to the manufacturer's protocol (Invitrogen). Total RNAs from various areas of the adult rat brain, from rat brain at birth (P0) and from embryonic rat brain at stage E16.5, were prepared by Trizol extraction. RT reactions were performed from total RNAs (1 mg) using oligo(dT) primer and the SuperScript II Rnase H2 Reverse Transcriptase (Invitrogen), according to the manufacturer's instructions. One-twentieth of the reaction product was used for PCR amplification of 30 cycles with specific primers for human SRPX2, uPAR and GAPDH genes and their rat counterparts (Supplementary Material, Table S1) in a 9700 DNA thermocycler (Applera).
Generation of constructs
Human wild-type and p.N327S mutant SRPX2 corresponding coding sequences were amplified by RT -PCR from fibroblasts total RNAs of one control individual and of one RESDX patient (7), respectively, and subcloned into the appropriate vectors (see later). For co-IP experiments, the pcDNA4-SRPX2 constructs were obtained by RT -PCR amplification (primers TagF and TagR2) of the coding sequences of wild-type and p.N327S SRPX2 proteins and subsequent subcloning into pcDNA4/TO/mycHis (Invitrogen) in order to generate wild-type and mutant SRPX2-myc fusion proteins. The p.Y72S mutation and the chimpanzee variation (R at position 75 of SRPX2: R 75 ) were introduced into the wild-type construct using the XL Quickchange mutagenesis kit (Stratagene). For protein production in P. pastoris, the coding sequences of wild-type and p.N327S SRPX2 proteins were RT -PCR amplified with primers PICZ-F and PICZ-R2 and subcloned into the pPICZ production vector (Invitrogen). p.Y72S and R 75 were introduced into the wild-type construct using the XL Quickchange mutagenesis kit (Stratagene). Expression vectors containing the ADAMTS4, CTSB, NELL2, PCDH10 and WIF1 full-length coding sequences subcloned into p-Receiver-M03 were obtained commercially (Genecopeia Ltd). Full-length and partial human uPAR coding sequences were amplified by RT -PCRs from total RNAs of one control autopsy brain sample, using various combinations of primers: uPAR-F and uPAR-R (pAcGFP1-uPAR), uPAR-F and uPARD1-R (pAcGFP1-uPARD1), uPAR-F and uPARD2-R (pAcGFP1-uPARD12), uPAR-F and uPARD3-R (pAcGFP1-uPARD123), uPARD2-F and uPAR-R2 (pAcGFP1-uPARDD1). The various uPAR constructs were obtained by subcloning into pAcGFP1-N1 (Clontech), in order to produce fusion proteins with GFP tag at the C-termini. Control constructs that contained only the signal peptide of SRPX2 (pcDNA4-sp) and of uPAR (pAcGFP1-sp) were obtained by RT-PCR amplification of the corresponding coding sequences (SRPX2 signal peptide: primers TagF and SRPX2signal-R; uPAR signal peptide: primers uPAR-F and uPARsignal-R) and subcloning into pcDNA4/TO/mycHis and into pAcGFP1-N1, respectively. For AP experiments, the cDNA corresponding to a truncated SRPX2 protein lacking its signal peptide was amplified by RT-PCR (primers SRPX2-deltaSP-F and SRPX2-R) and inserted into pAPtag-5 plasmid at the C-terminus of the AP tag (pAPtag-SRPX2). In order to allow for the accurate expression of a uPAR protein able to anchor to the plasma membrane through a GPI group, a stop codon was reintroduced into the pAcGFP1-N1/uPAR construct a the end of the uPAR coding sequence and just 5 0 to the GFP coding sequence (pAcGFP1-N1/uPARstop) using the XL Quickchange mutagenesis kit (Stratagene) and the appropriate primers. All insert sequences of the constructs used in this study were confirmed by automated sequencing (GATC Biotech) and any unwanted mutation was reverted with the XL Quickchange mutagenesis kit (Stratagene) and using the appropriate primers. The list of all primers used for the constructs and for mutagenesis is given in Supplementary Material, Table S1 .
Cell cultures and transfections
Human embryonic kidney (HEK293T) cells and African green monkey kidney fibroblast (COS-7) cells were grown in 5% CO2 at 378C in DMEM nutrient mixture (Lonza) supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin and 10% fetal calf serum. When cells reached 80-90% confluence, they were harvested with 0.25% trypsin and 0.05% EDTA in 10 mM sodium phosphate, 0.15 M NaCl, pH 7.4 buffer (PBS, phosphate-buffered saline) and aliquots of dissociated cells were plated on 100 mm diameter Petri dishes. At 60% confluence, HEK or COS-7 cells were transiently transfected with the appropriate plasmids using the JetPei (PolyPlus Transfection) kit and according to the manufacturer's protocol.
Surface binding assays of AP fusion proteins
AP-tagged fusion SRPX2 protein was produced by transient transfection of COS-7 cells with pAPtag-5-SRPX2 recombinant plasmid (pAPtag-SRPX2) (61) . As a control, AP was produced by transfecting the non-recombinant pAPtag-5 plasmid (pAPtag). After 24 h of culture in DMEM medium, transfected cells were grown for an additional 48 h-period in OptiMEM medium (Gibco). The extracellular media were then recovered and concentrated 8-fold on Amicon columns (Millipore) and checked for the presence of AP-SRPX2 fusion protein by SDS-PAGE and immunoblotting (Fig. 3 ) using anti-SRPX2 antibody (1/500, PTG-Lab; Supplementary Material, Fig. S5 ).
Parental (untransfected) COS-7 cells or COS-7 cells that had been transfected with pAcGFP1-N1/uPARstop (COS-7/ uPAR) were plated 5 h after transfection in four-well coated slides (Lab-tek II CC2, Nunc). Forty-eight hours later, slides were washed twice with Hank's balanced salt solution
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Human Molecular Genetics, 2008, Vol. 17, No. 23 (HBAS) and the cells were incubated with equally concentrated AP or AP-SRPX2 for 90 min at 378C. Cultures were then washed six times with HBAS. Cells were fixed with 4% paraformaldehyde for 15 s. at room temperature and washed two times in HBS (10 mM Hepes pH7, 150 mM NaCl). Slides were incubated at 658C for 100 min to heat-inactivate the endogenous AP activity, and the AP-SRPX2 binding was revealed in the presence of nitro blue tetrazolium and BCIP (5-bromo-4-chloro-3-indolyl phosphate) (Vector). Slides were mounted in Aquatex (Merck). Sections were observed with a microscope (Leica, CTR5000) and camera (Leica DFC300FX).
Co-IP experiments
Co-IP experiments using transfected HEK293T cells were done as follows: 48 h after co-transfection with the appropriate constructs, HEK293T cells were lysed in 50 mM Tris, pH 7.4, 1% Triton X-100, 10 mM MgCl 2 and a cocktail of protease inhibitors. After centrifugation (15 000g, 48C, 10 min), the lysate was precleared 2 h on 50 ml of anti-IgG Agarose beads (Sigma). One microgram of rabbit anti-myc antibody (Sigma) was also incubated on 50 ml of anti-IgG Agarose beads for 2 h at 48C. Precleared lysates were then incubated on antibody-coupled beads overnight at 48C. Non-specific binding was removed from the agarose beads by washing twice with the lysis buffer, twice with 50 mM Tris, pH 7.4, 150 mM NaCl and twice with 50 mM Tris, pH 7.4. The immunoprecipitated SRPX2 protein and SRPX2 partner were dissociated from the Agarose beads by heating at 958C for 5 min in Laemmli's sample buffer. Co-IP experiments on protein extracts from the rolandic area were performed as follows: protein extraction was done as already described (62) . Washed brain tissue was homogenized in 4 -8 volumes of STMDPS (50 mM Tris, pH 7.4, 250 mM sucrose, 5 mM MgCl 2 ). The homogenate was centrifuged 15 min at 1300g, 48C and the supernatant was aliquoted and conserved at 2808C. Immunoprecipitations were performed with Size Pimary Immunoprecipitation Kit, according to the manufacturer's protocol (Pierce): after washing with coupling buffer, 100 ml of AminoLink Plus 50% Gel Slurry were incubated overnight with 50 mg of rabbit anti-SRPX2 antibody (Supplementary Material, Fig. S5) (7) or nonimmune rabbit IgG (Jackson Laboratories) diluted in 200 ml of coupling buffer þ 2 ml of Reducing Agent. After several washes, the antibody-coupled gel was incubated overnight at 48C with 500 ml of protein extract. Proteins were then eluted in 3 Â 50 ml of ImmunoPure Elution buffer.
Western blot analysis
After separation on SDS-containing 7 -10% polyacrylamide gels (SDS -PAGE), the proteins were transferred on a nitrocellulose membrane (Protran, Schleicher and Schuell). After blocking the non-specific sites with 5% non-fat milk in Tris buffered saline, the membrane was incubated with primary antibodies: mouse anti-myc (1/5000, Roche), mouse anti-GFP (1/8000, Clontech), mouse anti-GAPDH (1/10 000, Chemicon), rabbit anti-SRPX2 (1/500, PTG-Lab; Supplementary Material, Fig. S5 ) or rabbit anti-uPAR (1/500, American Diagnostica) for 1 h to overnight, and then incubated with anti-mouse or anti-rabbit HRP-conjugated antibodies (1/5000, Jackson Immunoresearch). The membrane were revealed with ECL Plus Western Blotting Detection System (Amersham, GE Healthcare) and exposed to autoradiographic film (BioMax MS films, Eastman-Kodak).
Immunocyto-and immunohistochemistry
COS-7 cells were transfected as described earlier and fixed in 4% paraformaldehyde for 20 min at room temperature and then neutralized with 50 mM NH 4 Cl. Non-specific binding was blocked in 0.1 M sodium phosphate, pH 7.4, with 10% normal goat serum, supplemented with 0.5% Triton X-100. Cells were incubated with a polyclonal anti-uPAR antibody (1/400, American Diagnostica). The secondary antibodies were anti-rabbit antibodies conjugated to Alexa 488 (1/400, Invitrogen). Coverslips were mounted in Vectashield (Vector). Images were obtained with confocal microscope Leica TCS SP5, 1024 Â 1024 pixel images, 0.2 mm step, Â3 line average, Â3 frame accumulation.
Immunohistochemistry experiments were performed as already described (7) . Briefly, human and Wistar rat adult brain tissues were frozen with liquid nitrogen vapors and stored at 2808C until use. Wistar rat embryos at E16.5 and newborns (P0) were sacrificed and total bodies (E16.5) or heads (P0) were frozen with liquid nitrogen vapors and stored at 2808C until use. Serial sections (14 mm with a Microm cryostat) of human and rat samples were dipped in 4% paraformaldehyde in PBS (pH 7.4) for 30 min and then rinsed in PBS. Paraformaldehyde was neutralized by 0.1 M Glycine. Non-specific binding was blocked and tissue was permeabilized in 0.1 M phosphate buffer, pH 7.4, supplemented with 10% NGS or NHS and 0.01% Triton. Primary antibodies were incubated 1 h to overnight at 378C. The following antibodies were used as primary antibodies: rabbit anti-SRPX2 antibody (1/50) (7) (Supplementary Material, Fig. S5 ), rabbit anti-uPAR antibody (1/25, SantaCruz) and mouse anti-MAP2 antibody (1/50, Sigma). Secondary antibodies were incubated 1 h at 378C using anti-rabbit Alexa 488-conjugated antibodies (1/400, Invitrogen) or anti-mouse Alexa 568-conjugated antibodies (1/400, Invitrogen). For peroxidase detection, the Vectastain ABC kit and its substrate Peroxidase AEC kit (Vector, Abcyss) were used according to the manufacturer's protocol. In each experiment, negative controls included slides incubated with non-immune rabbit or mouse IgG (Jackson Laboratories). Sections were observed with a microscope (Leica, CTR5000) and camera (Leica DFC300FX).
Production of SRPX2 proteins in P. pastoris EasySelect Pichia Expression kit (Invitrogen) was used to produce recombinant SRPX2 proteins in P. pastoris according to the manufacturer's protocol. Briefly, pPICZ-SRPX2 plasmids for the production of the wild-type, pathogenic mutant (p.Y72S, p.327S) and chimpanzee (R 75 ) SRPX2 proteins were linearized with PmeI restriction enzyme and introduced in X-33 strain by EasyComp transformation (Invitrogen). Clones that were able to metabolize methanol were then selected on the basis of protein production efficiency. For production, one 0 , room temperature) and pellets were stored at 2808C if necessary. Pellets were resuspended in breaking buffer to 50 , OD 600 , 100 and equal volume of acid-washed glass beads was added. The mixture was vortexed for 30 s and then incubated on ice for 30 s; this was repeated seven more times and the mixture was then centrifugated (12 000g, 10 0 , 48C). The insoluble proteins were extracted from the pellet in the same way in 8 M urea. Protino Ni-IDA columns (Macherey-Nagel) were used to purify the proteins in denaturating conditions, according to the manufacturer's protocol. Briefly, columns were equilibrated in denaturating buffer (50 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl, 8 M urea). The samples were then charged and the resin was washed two times. Elution was done in denaturating buffer þ 250 mM imidazole. The first fraction of elution was concentrated about 10-folds on Amicon (Millipore) and dialyzed in Slide-a-lyser cassettes (Pierce) against 10 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl, 0,05% Tween20.
Protein production and purification were checked by SDS -PAGE and by mass spectrometry (Supplementary Material,  Fig. S4 ). For mass spectrometry, proteins were 'in gel' digested in excised gel plugs, using sequencing grade modified porcine trypsin (12.5 ng/l, Promega). The peptides were extracted, dried in a vacuum, centrifuged and resuspended in 10-20 ml of 0.1% TFA.
For MALDI mass spectrometry identification (wt and R 75 SRPX2 proteins), the peptide mixture resulting from protein digestion was then analyzed using a Ettan pro MALDI time-of-flight mass spectrometer (Amersham biosciences) in positive ion reflector mode. 0.3 ml of the Peptide mixture was co-crystallized on the MALDI target with an equal amount of matrix solution (3 mg/ml of a-cyano-4-hydroxycinnamic acid in 50% acetonitrile) in the presence of 0.5% TFA. Alternatively, peptide mixtures derived from proteins were desalted and concentrated using zip tips (Millipore) and deposited onto the MALDI target by elution with the matrix solution. Proteins were identified by the Mascot (Matrix science Ltd) software that queries Swissprot database.
For Nano electrospray MS/MS identification (p.Y72S SRPX2 protein), mass spectrometric measurements were done on a LCQ TM Deca XP Plus ion trap mass spectrometer (ThermoFinnigan) equipped with a LCQ TM nanospray ionization source. Digested peptides were separated using an Ettan MDLC chromatographic system (GE Healthcare). The chromatographic system was piloted by Unicorn 5.01 software (GE Healthcare). Three dependant MS/MS spectra of the three most intense peaks were collected following one full scan mass spectrum. Extracted MS/MS spectra were automatically assigned to the best matching peptide sequence using the Mascot software against Swissprot Database.
SPR analysis of SRPX2/uPAR interactions
SPR experiments were performed at 258C on a CM5 sensor chip with a Biacore 3000 instrument (GE Healthcare). GST (control flow cell) or GST-uPAR (experiment flow cell) proteins were covalently immobilized (50 -80 fmol) using amine coupling chemistry according to the manufacturer's instructions. GST protein was produced as already described (27) and GST-uPAR fusion protein was obtained from Abnova Ltd. The single-cycle kinetic method (26, 27) was used to analyze the binding of SRPX2 proteins (wild-type, pY72S and R 75 ) to GST-uPAR (Supplementary Material,  Fig. S6 ). SRPX2 proteins were serially diluted 2-fold in running buffer (10 mM NaH 2 PO 4 , 300 mM NaCl, 0.05% Tween20), yielding concentrations ranging from 7 to 115 nM. Samples were injected sequentially at 30 ml/min in increasing concentrations over both the ligand and the reference surfaces. Blank runs (buffer) were also included prior to SRPX2 injections and used to double-reference the binding data. Sensorgrams obtained with control flow cell were systematically subtracted from those obtained with GST-uPAR flow cells. Subtracted sensorgrams were globally fitted with the 1:1 titration kinetic binding model with BIAevaluation 4.1 software. Three independent experiments were done and used to calculate an average K D for each uPARbinding of SRPX2 wild-type and mutant proteins (Table 3) .
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